首页> 外文期刊>Biochemistry >Structural basis for assembly of the Mn~(IV)/Fe~(III) cofactor in the class ic ribonucleotide reductase from chlamydia trachomatis
【24h】

Structural basis for assembly of the Mn~(IV)/Fe~(III) cofactor in the class ic ribonucleotide reductase from chlamydia trachomatis

机译:沙眼衣原体ic核糖核苷酸还原酶中Mn〜(IV)/ Fe〜(III)辅因子组装的结构基础

获取原文
获取原文并翻译 | 示例
           

摘要

The class Ic ribonucleotide reductase (RNR) from Chlamydia trachomatis (Ct) employs a Mn~(IV)/Fe~(III) cofactor in each monomer of its β_2 subunit to initiate nucleotide reduction. The cofactor forms by reaction of Mn~(II)/Fe~(II)-β_2 with O _2. Previously, in vitro cofactor assembly from apo β_2 and divalent metal ions produced a mixture of two forms, with Mn at site 1 (Mn~(IV)/Fe~(III)) or site 2 (Fe~(III)/Mn~(IV)), of which the more active Mn~(IV)/Fe~(III) product predominates. Here we have addressed the basis for metal site selectivity by determining X-ray crystal structures of apo,Mn~(II), andMn~(II)/Fe ~(II) complexes of Ct β_2. A structure obtained anaerobically with equimolarMn~(II), Fe~(II), and apoprotein reveals exclusive incorporation of Mn~(II) at site 1 and Fe~(II) at site 2, in contrast to the more modest site selectivity achieved previously. Site specificity is controlled thermodynamically by the apoprotein structure, as only minor adjustments of ligands occur upon metal binding. Additional structures imply that, by itself,Mn~(II) binds in either site. Together, the structures are consistent with a model for in vitro cofactor assembly in which Fe~(II) specificity for site 2 drives assembly of the appropriately configured heterobimetallic center, provided that Fe~(II) is substoichiometric. This model suggests that use of a Mn~(IV)/Fe ~(II)I cofactor in vivo could be an adaptation to Fe~(II) limitation. A 1.8 ? resolution model of theMn~(II)/Fe ~(II)-β_2 complex reveals additional structural determinants for activation of the cofactor, including a proposed site for side-on (η~2) addition of O_2 to Fe~(II) and a short (3.2 ?)Mn~(II)-Fe~(II) interionic distance, promoting formation of the Mn~(IV)/Fe~(IV) activation intermediate.
机译:沙眼衣原体(Ct)的Ic类核糖核苷酸还原酶(RNR)在其β_2亚基的每个单体中使用Mn〜(IV)/ Fe〜(III)辅因子来启动核苷酸还原。辅因子是通过Mn〜(II)/ Fe〜(II)-β_2与O _2反应形成的。以前,脱辅基β_2和二价金属离子的体外辅因子组装产生了两种形式的混合物,其中Mn在位点1(Mn〜(IV)/ Fe〜(III))或位点2(Fe〜(III)/ Mn〜 (IV)),其中活性较高的Mn〜(IV)/ Fe〜(III)产物占主导地位。在这里,我们通过确定Ctβ_2的apo,Mn〜(II)和Mn〜(II)/ Fe〜(II)配合物的X射线晶体结构,解决了金属位点选择性的基础。与等摩尔的Mn〜(II),Fe〜(II)和脱辅基蛋白厌氧地获得的结构显示,Mn〜(II)在位点1和Fe〜(II)在位点2排他地掺入,与位点选择性较适度相反先前。位置特异性是由载脂蛋白结构热力学控制的,因为在金属结合时仅对配体进行了很小的调整。另外的结构暗示,Mn〜(II)本身在任一位点结合。在一起,该结构与体外辅因子组装的模型一致,其中Fe〜(II)对位点2的特异性驱动适当配置的异双金属中心的组装,前提是Fe〜(II)是亚化学计量的。该模型表明,在体内使用Mn〜(IV)/ Fe〜(II)I辅助因子可能是对Fe〜(II)限制的适应。 1.8? Mn〜(II)/ Fe〜(II)-β_2配合物的拆分模型揭示了辅助因子活化的其他结构决定因素,包括提议的O_2侧向(η〜2)O_2加入Fe〜(II)的位点和较短的(3.2Ω)Mn〜(II)-Fe〜(II)离子间距离,促进了Mn〜(IV)/ Fe〜(IV)活化中间体的形成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号